Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial

[1]  P. Widschwendter,et al.  Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial , 2019, Breast Cancer Research and Treatment.

[2]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[3]  E. Perez,et al.  Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. V. van't Veer,et al.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.

[5]  M. Beckmann,et al.  CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients , 2016, Tumor Biology.

[6]  M. Rezai,et al.  Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial , 2016, BMC Cancer.

[7]  M. Rezai,et al.  Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial , 2016, Geburtshilfe und Frauenheilkunde.

[8]  S. Paik,et al.  Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. , 2015, The Lancet. Oncology.

[9]  S. Barni,et al.  Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial , 2015, The Lancet.

[10]  R. Schulz-Wendtland,et al.  Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies , 2014, Breast Cancer Research and Treatment.

[11]  Wei Zhang,et al.  A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer , 2014, SpringerPlus.

[12]  R. Souchon,et al.  DEGRO practical guidelines for radiotherapy of breast cancer IV , 2014, Strahlentherapie und Onkologie.

[13]  Tanja Fehm,et al.  Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients , 2014, Journal of the National Cancer Institute.

[14]  R. Laing,et al.  Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. , 2014, The Lancet. Oncology.

[15]  M. Rezai,et al.  Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  S. Paik,et al.  Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Souchon,et al.  DEGRO practical guidelines: radiotherapy of breast cancer I , 2013, Strahlentherapie und Onkologie.

[18]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  R. Souchon,et al.  DEGRO practical guidelines: radiotherapy of breast cancer II , 2013, Strahlentherapie und Onkologie.

[20]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[21]  D. Cutter,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.

[22]  James A Young,et al.  Bevacizumab added to neoadjuvant chemotherapy for breast cancer. , 2012, The New England journal of medicine.

[23]  V. Kataja,et al.  Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  M. Beckmann,et al.  Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment. , 2010, Anticancer research.

[26]  M. Rezai,et al.  Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Xueri Li,et al.  Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients:The FNCLCC PACS 01 Trial , 2009 .

[28]  Allen S Melemed,et al.  Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Souchon,et al.  DEGRO Practical Guidelines for Radiotherapy of Breast Cancer II , 2008, Strahlentherapie und Onkologie.

[30]  Janet A. Dunn,et al.  tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC) , 2008 .

[31]  E. Perez,et al.  Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.

[32]  M. Trudeau,et al.  Gemcitabine in the management of metastatic breast cancer: a systematic review , 2008, Breast Cancer Research and Treatment.

[33]  R. Souchon,et al.  DEGRO Practical Guidelines for Radiotherapy of Breast Cancer I , 2007, Strahlentherapie und Onkologie.

[34]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  T. Delozier,et al.  Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Dongsheng Tu,et al.  Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Inbar,et al.  Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[39]  D. Dodwell,et al.  Optimum anthracycline-based chemotherapy for early breast cancer. , 2001, The Lancet. Oncology.

[40]  D. Tu,et al.  Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Espié,et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.